vs
CATALYST PHARMACEUTICALS, INC.（CPRX）与BRC Group Holdings, Inc.（RILY）财务数据对比。点击上方公司名可切换其他公司
BRC Group Holdings, Inc.的季度营收约是CATALYST PHARMACEUTICALS, INC.的1.2倍（$188.3M vs $152.6M），BRC Group Holdings, Inc.净利率更高（47.9% vs 34.5%，领先13.4%），CATALYST PHARMACEUTICALS, INC.同比增速更快（7.6% vs -21.9%），过去两年CATALYST PHARMACEUTICALS, INC.的营收复合增速更高（24.5% vs -15.4%）
Catalyst Pharmaceuticals是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于罕见病药物研发。核心产品包括用于治疗兰伯特-伊顿肌无力综合征（LEMS）的氨吡啶磷酸盐，商品名为Firdapse。该药物2018年11月获FDA批准，除原有成人适应症外，还可用于6岁及以上的LEMS儿童患者。
CPRX vs RILY — 直观对比
营收规模更大
RILY
是对方的1.2倍
$152.6M
营收增速更快
CPRX
高出29.5%
-21.9%
净利率更高
RILY
高出13.4%
34.5%
两年增速更快
CPRX
近两年复合增速
-15.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $152.6M | $188.3M |
| 净利润 | $52.7M | $90.3M |
| 毛利率 | 82.9% | 79.5% |
| 营业利润率 | 40.5% | 32.3% |
| 净利率 | 34.5% | 47.9% |
| 营收同比 | 7.6% | -21.9% |
| 净利润同比 | -5.8% | 1710.8% |
| 每股收益（稀释后） | $0.40 | $2.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CPRXRILY
| Q4 25 | $152.6M | $188.3M | ||
| Q3 25 | $148.4M | $215.3M | ||
| Q2 25 | $146.6M | $188.2M | ||
| Q1 25 | $141.4M | $197.2M | ||
| Q4 24 | $141.8M | $241.0M | ||
| Q3 24 | $128.7M | $225.5M | ||
| Q2 24 | $122.7M | $256.0M | ||
| Q1 24 | $98.5M | $263.4M |
净利润CPRXRILY
| Q4 25 | $52.7M | $90.3M | ||
| Q3 25 | $52.8M | $91.1M | ||
| Q2 25 | $52.1M | $139.5M | ||
| Q1 25 | $56.7M | $-10.0M | ||
| Q4 24 | $55.9M | $-5.6M | ||
| Q3 24 | $43.9M | $-284.4M | ||
| Q2 24 | $40.8M | $-433.6M | ||
| Q1 24 | $23.3M | $-49.2M |
毛利率CPRXRILY
| Q4 25 | 82.9% | 79.5% | ||
| Q3 25 | 84.7% | 83.7% | ||
| Q2 25 | 85.9% | 81.3% | ||
| Q1 25 | 87.3% | 81.4% | ||
| Q4 24 | 84.7% | 79.8% | ||
| Q3 24 | 85.0% | 82.1% | ||
| Q2 24 | 87.4% | 84.5% | ||
| Q1 24 | 87.3% | 85.3% |
营业利润率CPRXRILY
| Q4 25 | 40.5% | 32.3% | ||
| Q3 25 | 44.7% | 30.4% | ||
| Q2 25 | 45.2% | 5.7% | ||
| Q1 25 | 44.8% | -31.2% | ||
| Q4 24 | 44.3% | -69.2% | ||
| Q3 24 | 39.6% | -36.4% | ||
| Q2 24 | 44.2% | -90.8% | ||
| Q1 24 | 27.5% | -6.1% |
净利率CPRXRILY
| Q4 25 | 34.5% | 47.9% | ||
| Q3 25 | 35.6% | 42.3% | ||
| Q2 25 | 35.6% | 74.1% | ||
| Q1 25 | 40.1% | -5.1% | ||
| Q4 24 | 39.4% | -2.3% | ||
| Q3 24 | 34.1% | -126.1% | ||
| Q2 24 | 33.2% | -169.4% | ||
| Q1 24 | 23.6% | -18.7% |
每股收益（稀释后）CPRXRILY
| Q4 25 | $0.40 | $2.78 | ||
| Q3 25 | $0.42 | $2.91 | ||
| Q2 25 | $0.41 | $4.50 | ||
| Q1 25 | $0.45 | $-0.39 | ||
| Q4 24 | $0.44 | $-0.01 | ||
| Q3 24 | $0.35 | $-9.39 | ||
| Q2 24 | $0.33 | $-14.35 | ||
| Q1 24 | $0.19 | $-1.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $709.2M | $226.6M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $954.3M | $-171.5M |
| 总资产 | $1.1B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CPRXRILY
| Q4 25 | $709.2M | $226.6M | ||
| Q3 25 | $689.9M | $184.2M | ||
| Q2 25 | $652.8M | $267.4M | ||
| Q1 25 | $580.7M | $138.3M | ||
| Q4 24 | $517.6M | $146.9M | ||
| Q3 24 | $442.3M | $159.2M | ||
| Q2 24 | $375.7M | $236.9M | ||
| Q1 24 | $310.4M | $190.7M |
总债务CPRXRILY
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | — | $1.3B | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CPRXRILY
| Q4 25 | $954.3M | $-171.5M | ||
| Q3 25 | $920.2M | $-260.5M | ||
| Q2 25 | $856.0M | $-351.7M | ||
| Q1 25 | $794.3M | $-496.8M | ||
| Q4 24 | $727.6M | $-488.2M | ||
| Q3 24 | $660.9M | $-497.6M | ||
| Q2 24 | $608.7M | $-218.3M | ||
| Q1 24 | $561.4M | $228.4M |
总资产CPRXRILY
| Q4 25 | $1.1B | $1.7B | ||
| Q3 25 | $1.1B | $1.7B | ||
| Q2 25 | $971.9M | $1.5B | ||
| Q1 25 | $908.9M | $1.5B | ||
| Q4 24 | $851.4M | $1.8B | ||
| Q3 24 | $772.0M | $2.2B | ||
| Q2 24 | $706.4M | $3.2B | ||
| Q1 24 | $646.7M | $5.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $44.9M | $26.2M |
| 自由现金流经营现金流 - 资本支出 | $44.9M | — |
| 自由现金流率自由现金流/营收 | 29.4% | — |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | 0.85× | 0.29× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流CPRXRILY
| Q4 25 | $44.9M | $26.2M | ||
| Q3 25 | $32.4M | $-60.6M | ||
| Q2 25 | $71.3M | $-25.6M | ||
| Q1 25 | $60.0M | $184.0K | ||
| Q4 24 | $70.9M | $-2.7M | ||
| Q3 24 | $72.9M | $19.5M | ||
| Q2 24 | $64.1M | $111.5M | ||
| Q1 24 | $31.9M | $135.4M |
自由现金流CPRXRILY
| Q4 25 | $44.9M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $71.3M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $70.8M | — | ||
| Q3 24 | $72.6M | — | ||
| Q2 24 | $64.1M | — | ||
| Q1 24 | $31.7M | — |
自由现金流率CPRXRILY
| Q4 25 | 29.4% | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 48.6% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 49.9% | — | ||
| Q3 24 | 56.4% | — | ||
| Q2 24 | 52.3% | — | ||
| Q1 24 | 32.2% | — |
资本支出强度CPRXRILY
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.2% | — | ||
| Q2 24 | 0.0% | — | ||
| Q1 24 | 0.2% | — |
现金转化率CPRXRILY
| Q4 25 | 0.85× | 0.29× | ||
| Q3 25 | 0.61× | -0.66× | ||
| Q2 25 | 1.37× | -0.18× | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.66× | — | ||
| Q2 24 | 1.57× | — | ||
| Q1 24 | 1.37× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CPRX
| Firdapse | $97.6M | 64% |
| Agamree | $35.3M | 23% |
| Fycompa | $19.6M | 13% |
RILY
| Transferred At Point In Time | $101.4M | 54% |
| Wealth Management Segment | $30.7M | 16% |
| Corporate Finance Consulting And Investment Banking Fees | $27.1M | 14% |
| Services And Fees | $24.8M | 13% |
| Commissions Fees And Reimbursed Expenses | $4.8M | 3% |
